104 related articles for article (PubMed ID: 30573522)
1. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Dong Q; Du Y; Li H; Liu C; Wei Y; Chen MK; Zhao X; Chu YY; Qiu Y; Qin L; Yamaguchi H; Hung MC
Cancer Res; 2019 Feb; 79(4):819-829. PubMed ID: 30573522
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt SJ; Krastev DB; Brandsma I; Dréan A; Song F; Aleksandrov R; Harrell MI; Menon M; Brough R; Campbell J; Frankum J; Ranes M; Pemberton HN; Rafiq R; Fenwick K; Swain A; Guettler S; Lee JM; Swisher EM; Stoynov S; Yusa K; Ashworth A; Lord CJ
Nat Commun; 2018 May; 9(1):1849. PubMed ID: 29748565
[TBL] [Abstract][Full Text] [Related]
3. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
4. PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
Fröhlich LM; Villar-Miyar A; Heintze T; Sauer B; Schittek B
Int J Cancer; 2024 Jul; 155(2):203-210. PubMed ID: 38619111
[TBL] [Abstract][Full Text] [Related]
5. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Chu YY; Yam C; Chen MK; Chan LC; Xiao M; Wei YK; Yamaguchi H; Lee PC; Han Y; Nie L; Sun X; Moulder SL; Hess KR; Wang B; Hsu JL; Hortobagyi GN; Litton J; Chang JT; Hung MC
Am J Cancer Res; 2020; 10(2):648-661. PubMed ID: 32195033
[TBL] [Abstract][Full Text] [Related]
6. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells.
Liu H; Zhang Z; Chi X; Zhao Z; Huang D; Jin J; Gao J
Sci Rep; 2016 Aug; 6():31009. PubMed ID: 27484730
[TBL] [Abstract][Full Text] [Related]
7. Gasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models.
Wang S; Chang CW; Huang J; Zeng S; Zhang X; Hung MC; Hou J
J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37883181
[TBL] [Abstract][Full Text] [Related]
8. NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors.
Wang Y; Liu X; Zuo X; Wang C; Zhang Z; Zhang H; Zeng T; Chen S; Liu M; Chen H; Song Q; Li Q; Yang C; Le Y; Xing J; Zhang H; An J; Jia W; Kang L; Zhang H; Xie H; Ye J; Wu T; He F; Zhang X; Li Y; Zhou G
Cell Genom; 2024 May; 4(5):100550. PubMed ID: 38697125
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment.
Min W; Wang Y; Shen H; Zheng M; Tong C; Shen H; Wang D; Zhu Y; Wang X; Xiao Y; Zhang XY; Yang P
Eur J Med Chem; 2024 Jan; 264():116025. PubMed ID: 38086189
[TBL] [Abstract][Full Text] [Related]
10. Imaging PARP Upregulation with [
Ndlovu H; Lawal I; Mokoala K; Disenyane D; Nkambule N; Bassa S; Mzizi Y; Bida M; Sathekge M
J Nucl Med; 2024 Apr; 65(4):665-666. PubMed ID: 38050115
[No Abstract] [Full Text] [Related]
11. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models.
Keklikoglou I; Cianciaruso C; Güç E; Squadrito ML; Spring LM; Tazzyman S; Lambein L; Poissonnier A; Ferraro GB; Baer C; Cassará A; Guichard A; Iruela-Arispe ML; Lewis CE; Coussens LM; Bardia A; Jain RK; Pollard JW; De Palma M
Nat Cell Biol; 2019 Feb; 21(2):190-202. PubMed ID: 30598531
[TBL] [Abstract][Full Text] [Related]
13. Exploring and comparing adverse events between PARP inhibitors.
LaFargue CJ; Dal Molin GZ; Sood AK; Coleman RL
Lancet Oncol; 2019 Jan; 20(1):e15-e28. PubMed ID: 30614472
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
Francica P; Rottenberg S
Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Xu F; Sun Y; Yang SZ; Zhou T; Jhala N; McDonald J; Chen Y
Int J Cancer; 2019 Jul; 145(2):474-483. PubMed ID: 30614530
[TBL] [Abstract][Full Text] [Related]
16. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
17. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
[TBL] [Abstract][Full Text] [Related]
18. Cancer statistics, 2020.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2020 Jan; 70(1):7-30. PubMed ID: 31912902
[TBL] [Abstract][Full Text] [Related]
19. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
Li TE; Wang S; Shen XT; Zhang Z; Chen M; Wang H; Zhu Y; Xu D; Hu BY; Wei R; Zheng Y; Dong QZ; Qin LX
Front Immunol; 2020; 11():589997. PubMed ID: 33193421
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
Lee EK; Matulonis UA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
